Tagged with

Denmark Despite its diminutive size, Denmark boasts a world-renowned healthcare and life science industry containing both household pharma giants as well as a robust network of academia, a host of niche service providers, and a growing throng of biotech start-ups. And with life science exports surpassing EUR 23 billion last year…

Denmark When it comes to Denmark’s flourishing local biotech scene, the country is again clearly punching far above its weight. The EU member state has already managed to muster world-class expertise in areas like peptide chemistry and metabolic disorders, anchored by the success stories of homegrown entities that made it big…

Denmark Public Health Reimagined Denmark’s total health expenditure as a share of GDP has increased moderately over the past decade with the country spending 278 billion KKR (37.2 billion euros) in 2024, of which 83% was financed directly from government health schemes. Yet despite the country’s well-earned reputation for delivering high…

Denmark Making Life Sciences Strategic The super-sized contribution of the life sciences sector to Denmark’s national economy can hardly be overstated. With over 100,000 professionals currently engaged in biotech and pharmaceuticals across the country, Denmark already ranks as one of the European Union member states with the largest proportion of the…

Europe Affordability is not necessarily the main barrier to better rare disease therapy access in Europe. Across the continent, orphan availability correlates poorly with GDP per capita, but strongly with health technology assessment methods, speed of pricing and reimbursement, and central vs regional decision-making. Better system design – rather than simply…

Global First published in ISPOR’s Value & Outcomes Spotlight magazine, Shirley V. Wang, PhD, MSc of Brigham and Women’s Hospital, Harvard Medical School, argues that there is an urgent need for transparency in health economics and outcomes research (HEOR). Wang posits that the growing reliance on real-world evidence (RWE) in healthcare…

Switzerland SpiroChem has evolved from a niche ETH Zurich spin-out into a global discovery partner recognised for tackling some of the most complex challenges in modern drug design. Over more than a decade, co-founder and CEO Thomas Fessard has steered the company’s transformation from a product-focused catalogue into a solution-driven, modality-agnostic…

Switzerland Giancarlo Benelli, SVP, Head of Europe at BeOne Medicines (BeOne), draws on nearly three decades of pharmaceutical leadership to drive the company’s rapid growth in oncology and haematology in Europe, with flagship assets like zanubrutinib and tislelizumab. Over the last few years, BeOne has greatly expanded its clinical trials in…

China This week’s China healthcare and pharma roundup from PharmaBoardroom content partner Selesta highlights Atom Bioscience’s HKEX IPO, Ark Biosciences’ pipeline funding, Mabwell’s USD 1 billion siRNA deal, HiDiamond Bio’s Pre-Series A, and Enrui Kainuo’s CAR-NK cell therapy financing, alongside updates on IASO Bio’s CAR-T long-term data, Fosun’s breast cancer drug…

Europe Rainer Westermann of European life science venture capital lobby group, the Life Sciences Acceleration Alliance, lays out a policy roadmap for how innovative European pharma can continue to grow and thrive against a backdrop of trade uncertainty and precarious US-EU relations.   The US/EU trade deal was presented as necessary…

LatAm Dr Jarbas Barbosa, Director of the Pan American Health Organization (PAHO), discusses the organisation’s evolution from pandemic response to comprehensive health system transformation, regional production capabilities, and the imperative for multilateral cooperation in an increasingly fragmented global landscape.   The Americas, in their extraordinary diversity, are a living laboratory Could…

Switzerland Marc Gitzinger, CEO and Founder of BioVersys, launched the company from his doctoral research at ETH Zurich on antibiotic resistance. Bioversys began with a tuberculosis programme; today, it owns two proprietary platforms to develop new antibiotics and leads with BV-100, advancing to Phase III for severe hospital infections. Gitzinger also…